Physician profile
Sean Patrick Ryan
NPI 1780904706
$10,391.54
in general payments reported to CMS, 2019-2025
34 companies · $2,997 in 2025
The $2,997 reported for 2025 was more than what 86% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.45 · 2020: $4,484 · 2021: $971 · 2022: $307 · 2023: $652 · 2024: $967 · 2025: $2,997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,407 · Travel and Lodging: $2,209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,407.09 |
| Travel and Lodging | $2,209.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,013.30 | 2020-2025 | Da Vinci Surgical System |
| Davol INC. | $391.93 | 2024 | Phasix Mesh |
| Abbvie INC. | $390.82 | 2023-2025 | Skyrizi, Rinvoq |
| Smith+Nephew, INC. | $246.89 | 2021-2025 | Pico 7, Renasys Touch, Renasys Go V2 Home |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $238.03 | 2022-2025 | Xifaxan, Trulance, Uceris |
| Endologix LLC | $215.50 | 2023 | |
| Qol Medical, LLC | $111.40 | 2023-2025 | Sucraid, Sucraid |
| Veryan Medical Incorporated | $94.31 | 2024 | Biomimics 3d Vascular Stent System |
| Shield Therapeutics INC | $59.18 | 2024 | |
| Janssen Biotech, INC. | $58.23 | 2022-2025 | Tremfya, Simponi, Simponi Aria |
| Intercept Pharmaceuticals, INC. | $48.14 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $46.37 | 2023 | Rebyota |
| Urgo Medical North America, LLC | $46.31 | 2024 | Urgok2, Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Medtronic, INC. | $43.71 | 2021 | |
| Genzyme Corporation | $43.11 | 2022-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $35.43 | 2022-2024 | Entyvio |
| Phathom Pharmaceuticals, INC. | $31.78 | 2024 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $26.61 | 2025 | Dupixent |
| Daiichi Sankyo INC. | $23.15 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $20.78 | 2023 | Opsumit, Uptravi |
| Celltrion USA INC. | $19.09 | 2025 | Vegzelma |
| Kci USA, INC. | $17.92 | 2023 | Activ.A.C., V.A.C. Veraflo |
| Novo Nordisk INC | $17.42 | 2024 | Wegovy |
| Conmed Corporation | $16.99 | 2025 | System 2450 |
| Avanos Medical | $16.88 | 2020 | |
| Paratek Pharmaceuticals, INC. | $16.55 | 2023 | Nuzyra |
| La Jolla Pharmaceutical Company | $15.07 | 2023 | Xerava |
| Bayer Healthcare Pharmaceuticals INC. | $13.88 | 2023 | |
| Aimmune Therapeutics, INC. | $13.58 | 2025 | Vowst |
| Lilly USA, LLC | $13.48 | 2025 | Omvoh |
| Ethicon US, LLC | $13.46 | 2022 | |
| Merck Sharp & Dohme LLC | $13.45 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $13.38 | 2020 | |
| Reprise Biomedical, INC. | $5.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.